Shots:

• The company expands its portfolio with the marketing of the 6th biosimilars in Canada. Inclunox and Inclunox HP (enoxaparin sodium solution for injection) is indicated for use in 6 indications of the reference Lovenox and Lovenox HP in oncology- immunology- and endocrinology
• Sandoz Canada has completed the pCPA negotiations for Inclunox and Inclunox HP- which is the first step in securing public reimbursement. The INESSS recommends that new biosimilar be listed on the List of Medications
• Inclunox (IV or SC) is an anticoagulant biosimilar and is available in multiple prefilled syringes. Health Canada has authorized Lovenox and Lovenox HP on Nov 05- 2020 for marketing in Canada

Ref: Sandoz| Image: Sandoz